Evidence mapPaperPMID 42073391Full record

ArticleLife (Basel, Switzerland)2026

Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment-A Single Center Case Series.

Alessandro Magnatta, Alice Verdelli, Virginia Corti, Luca Sanna, Manfredi Magliulo, Valentina Ruffo di Calabria, Elisabetta Magnaterra, Elena Biancamaria Mariotti, Simone Landini, Rachel Daher and 7 more

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alessandro MagnattaDepartment of Health Sciences, Section of Dermatology, University of Florence, 50134 Florence, Italy.ORCID 0009-0008-1701-8772
Alice VerdelliDepartment of Health Sciences, Rare Disease Dermatological Unit, Section of Dermatology, University of Florence, P. Palagi Hospital, 50125 Florence, Italy.ORCID 0000-0003-1982-888X
Virginia CortiDepartment of Health Sciences, Section of Dermatology, University of Florence, 50134 Florence, Italy.ORCID 0009-0009-3637-9845
Luca SannaDepartment of Health Sciences, Section of Dermatology, University of Florence, 50134 Florence, Italy.ORCID 0009-0004-0630-3501
Manfredi MagliuloDepartment of Health Sciences, Section of Dermatology, University of Florence, 50134 Florence, Italy.ORCID 0000-0003-0154-3173
Valentina Ruffo di CalabriaDepartment of Health Sciences, Section of Dermatology, University of Florence, 50134 Florence, Italy.ORCID 0000-0003-0307-6636
Elisabetta MagnaterraDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.ORCID 0000-0002-3263-4353
Elena Biancamaria MariottiAzienda Usl Toscana Nord Ovest, Division of Dermatology, San Luca Hospital, 55100 Lucca, Italy.ORCID 0000-0003-0388-1037
Simone LandiniDepartment of Health Sciences, Section of Dermatology, University of Florence, 50134 Florence, Italy.ORCID 0009-0007-5416-4392
Rachel DaherDepartment of Health Sciences, Section of Dermatology, University of Florence, 50134 Florence, Italy.
Irene BonanniDepartment of Health Sciences, Section of Dermatology, University of Florence, 50134 Florence, Italy.ORCID 0009-0007-8253-4127
Marta DonatiDermatology Department, University of Modena and Reggio Emilia, 41124 Modena, Italy.
Francesca GoriniUnit of Epidemiology of Rare Diseases and Congenital Anomalies, Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.ORCID 0000-0002-4619-6227
Alessio CoiUnit of Epidemiology of Rare Diseases and Congenital Anomalies, Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.ORCID 0000-0002-9816-3144
Ilaria Di DonatoRare Neurologic Disease Center, Azienda USL Toscana Centro, San Giuseppe Hospital, 50053 Empoli, Italy.
Cinzia PupilliSOSD Endocrinologia Azienda USL Toscana Centro, P.O. Piero Palagi Viale Michelangiolo 41, 50122 Florence, Italy.
Marzia CaproniDepartment of Health Sciences, Rare Disease Dermatological Unit, Section of Dermatology, University of Florence, P. Palagi Hospital, 50125 Florence, Italy.ORCID 0000-0002-7471-3471

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dercum's disease (DD) is a rare chronic disorder characterized by painful subcutaneous lipomas, mostly affecting overweight or obese middle-aged women. The etiology remains unclear, and evidence for medical treatments is limited. Surgical approaches may reduce pain but are associated with frequent relapses and are difficult to implement in extensive clinical pictures. We investigated the outcomes of multiple medical and surgical therapeutic strategies. Particularly, we explored immunomodulators (methotrexate and infliximab), used alone or combined with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide, as well as the dual GIP (glucose-dependent insulinotropic polypeptide)/GLP-1 RAs tirzepatide. Five patients with DD were included in this retrospective single-center case series. Baseline clinical data, medical history, and longitudinal information on Dermatology Life Quality Index (DLQI), Visual Analogue Scale (VAS) for pain, and body mass index (BMI) were collected from existing medical records and scheduled follow-up visits conducted since 2021. Clinical trajectories differed across patients and regimens. Methotrexate and infliximab coincided with variable and often transient improvements in pain and quality of life. Combination regimens including GLP-1 RAs were accompanied by weight reduction and, in selected patients, by sustained improvements in pain and DLQI. In other cases, the benefit was limited or absent. Adverse events were manageable and consistent with the known safety profiles of these drugs. In this small real-world case series, therapeutic responses in DD were highly individualized, underscoring the absence of standardized medical treatment and the need for patient-tailored strategies. The observed patterns suggest that immunomodulatory and incretin-based therapies may represent exploratory options in selected patients, especially when surgery is not feasible. However, controlled studies are needed to clarify their role.

Indexed as

BMIDercum diseaseGLP-1infliximabmethotrexatepainsemaglutidetirzepatidetreatmentweight

Identifiers

PMID42073391
PMCPMC13117391

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.